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Background. Pneumonia is a condition, where bacterial infections are implicated as the most common causes of morbidity and
mortality in humans. The actual burden of HIV-infected patients with pneumonia is not well documented in Mekelle region
of Ethiopia. This study estimated the prevalence of bacterial pneumonia in HIV patients, antimicrobial susceptibility patterns
of pathogens implicated in pneumonia, and associated risk factors in Mekelle zone, Tigray, Northern Ethiopia, during August-
December 2016. Methods. Sputum specimens were collected from 252 HIV seropositive individuals with suspected pneumonia.
Data on sociodemographics and risk factors were also collected using a structured questionnaire. Blood, Chocolate, and Mac
Conkey agar plates (Oxoid, Hampshire, UK) were used to grow the isolates. The isolated colonies were identified based on Gram
stain, colony morphology, pigmentation, hemolysis, and biochemical tests. The antimicrobial susceptibility test was performed
using the modified Kirby-Bauer disc diffusion method.The analysis was performed using SPSS version 22 and p-value < 0.05 with
corresponding 95% confidence interval (CI) was considered statistically significant. Results. Out of the 252 samples, 110 (43.7%)
were positive for various bacterial species. The predominant bacterial species were Klebsiella pneumoniae (n=26, 23.6 %) followed
by Streptococcus pneumoniae (n=17, 15.5 %), Escherichia coli (n=16, 14.5%), Klebsiella spp. (n=15, 13.6%), Staphylococcus aureus
(n=9, 8.2%), Enterobacter spp. (n=7, 6.3%), Pseudomonas aeruginosa (4, n=3.6%), Proteus spp. (n=4, 3.6%), Citrobacter freundii
(n=7, 6.3%), Streptococcus pyogenes (3, 2.7%), and Haemophilus inﬂuenzae (n=2, 1.8%). Young age (18-29), recent CD4+ count less
than 350 cells/mL, alcohol consumption, and HIV WHO stage II showed significant association with the occurrence of bacterial
pneumonia. Resistance to penicillin, co-trimoxazole, and tetracycline was observed in 81.8%, 39.8%, and 24.5% of the isolates,
respectively. Conclusions. The problem of pneumonia among HIV patients was significant in the study area. The high prevalence
of drug-resistant bacteria isolated from the patient’s samples possesses a health risk in immunocompromised HIV patients. There
is a need to strengthen and expand culture and susceptibility procedures for the administration of appropriate therapy to improve
patients management and care which may aid in decreasing the mortality.
1. Background
Respiratory infections are the leading cause of morbidity
and mortality in HIV-infected individuals [1]. It is also the
most frequent cause of hospital admission in HIV-infected
people worldwide with an incidence of 20-25 episodes per
100 hospital admissions per year [2]. About 70% of HIV
patients have a pulmonary complication during the evolution
of the disease, mainly as a consequence of infectious etiology
[2]. During respiration, the respiratory tract, especially nose,
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nasopharynx, and oropharynx, comes into contact with a
large number of bacteria that may cause life-threatening
respiratory infections [3]. Lower respiratory tract infections
(LRTIs) are among the most prevalent diseases of human
beings worldwide [4], which result in around 7million deaths
annually [5]. Pneumonia is an acute respiratory illness which
is one of the most common LRTI, mainly caused by bacteria,
viruses, and fungi [6, 7].
Bacterial pneumonia is the most frequent cause of pul-
monary infections, which is among the most common causes
of respiratory failure in HIV- infected patients [2, 8]. The
incidence of bacterial pneumonia in HIV-infected patients
ranges from 1.93 to 19.2% of cases per year in Nigeria
[9]. HIV-infected individuals have a sixfold greater risk of
bacterial pneumonia than the noninfected individuals [10]
and estimated greater than one-third of all persons with
AIDS will develop at least one episode of severe bacterial
pneumonia over the course of their HIV infection [10]. If
bacterial pneumonia is not properly treated, it causes further
complications leading to empyema, meningitis, pericarditis,
hepatitis, and arthritis [10].
The most common pathogens that cause bacterial pneu-
monia are S. pneumoniae, H. inﬂuenzae, K. pneumoniae, P.
aeruginosa, E. coli, and S. aureus [11]. Among this S. pneu-
moniae is considered the predominant bacterial pathogen
across all age groups and accounts for approximately 30% of
pneumonia cases [12].
The incidence of bacterial drug resistance is high due
to empirical drug administration and poor adherence to
treatment standards. Hence, specific antibiotic therapy is
fundamental to manage and control bacterial pneumonia in
HIV patients [13]. Therefore, identifying the bacterial cause
and performing antibiotic susceptibility testing are vital [2].
In Northern Ethiopia, there is a high prevalence of HIV-
infected patients [14].However, there is no studywhich shows
the real burden of bacterial pneumonia among HIV positive
individuals in this region. In addition, the antimicrobial
susceptibility patterns of the common bacterial agents for
pneumonia are not known. Therefore, this study was per-
formed to assess the burden of bacterial pneumonia, the risk
factors, and antimicrobial susceptibility of bacterial isolates in
HIV positive individuals with suspected pneumonia at ART
clinics of Mekelle zone, Tigray, Northern Ethiopia.
2. Methods
2.1. Study Design, Specimen Collection, and Transportation.
A multicentre cross-sectional study was conducted from
August-December 2016 at different ART clinics of Mekelle
zone, Tigray, Ethiopia. A total of 252 HIV patients with
suspected pneumoniawere included in the study based on the
inclusion/exclusion criteria. Sociodemographic, clinical, and
risk-factor related data were collected using a structured and
pretested questionnaire. Pneumonia suspected individuals
showing clinical symptoms such as shortness of breath,
chest pain, fever, chills, tiredness, and cough were examined
by clinicians and the sputum samples were collected and
transported to medical microbiology laboratory, Mekelle
University, College of Health Sciences by medical laboratory
technologists for analysis within 2 hrs or stored at 4∘C until
further processing.
2.2. Inclusion and Exclusion Criteria. HIV seropositive,
highly active antiretroviral therapy users and nonusers aged
≥ 18 with a diagnosis of pneumonia as described by the
clinician were included. Patients who were critically ill, who
cannot produce sputum, suspected pulmonary tuberculosis
and who took antibiotics during the past two week period
were excluded.
2.3. Specimen Processing. Smear was prepared from each
sputum sample for Gram staining and slides were examined
under low power field (l0X). Sputum samples with > 25
polymorphonuclear leukocytes and <10 epithelial cells were
accepted for culture. Samples that hadmore than 10 epithelial
cells and less than 25 polymorphonuclear leukocytes per low
power field were discarded [15, 16].
2.4. Cultivation and Identiﬁcation of Isolates. Blood, Choco-
late, and Mac Conkey agar plates (Oxoid, Hampshire, UK)
were prepared as per the manufacturers’ instructions. Using
a calibrated wire loop, approximately 0.1𝜇L purulent sputum
sample was streaked onto each agar plate. Chocolate agar
plates were incubated at 37∘C for 24 hours in a candle
jar. MacConkey agar and blood agar plates were incubated
aerobically at 37∘C for 24 hours [15, 16]. After incubation, the
plates were inspected for any growth and negative plates were
incubated for an additional 24 hours. Quantitative sputum
culture analysis was carried out and the significant bacterial
count was reported on observing an excess of 106 CFU/mL
[17]. More than 100 CFU were considered significant for
bacterial growth in this study. A single pure culture colony
of each isolate was stored in nutrient broth with 10% glycerol
stock solution for identification. Gram-positive cocci were
differentiated and identified based on Gram stain, patterns
of hemolysis on blood agar, colonial characteristics, catalase
test, coagulase test, optochin susceptibility, and bacitracin
susceptibility. Gram-negative bacteria were also identified
based on Gram stain, colonial morphology and pigmen-
tation, oxidase test, carbohydrate fermentation, H
2
S pro-
duction, citrate utilization, motility, indole formation, urea
hydrolysis and growth in blood agar with “X”, and “V” factors
for H. inﬂuenzae.
2.5. Antimicrobial Susceptibility Testing. The antimicrobial
susceptibility test was performed using the Kirby-Bauer disc
diffusion test method [16]. The antimicrobial discs used for
susceptibility testing were amikacin (AK,30𝜇g), ciprofloxacin
(CIP,5𝜇g), ceftriaxone (CTR,30𝜇g), chloramphenicol (C,10
𝜇g),co-trimoxazole (COT,25𝜇g), erythromycin (ERY,15𝜇g),
gentamicin (GN,10𝜇g), Methicillin (MET, 30𝜇g)penicillin
(P,10 units), and tetracycline (TE,30 𝜇g). Muller-Hinton agar
(MHA) plates were used for the nonfastidious organism,
whereas MHA supplemented with 5% sheep blood were
used for S. pneumoniae and Haemophilus spp. using a stan-
dard procedure [16]. The results were interpreted using the
guidelines described by the CLSI (2016) standards. Multidrug
resistance was defined by nonsusceptibility to at least one
BioMed Research International 3
agent in three or more antimicrobial categories as described
earlier by Magiorakos et al. [18].
2.6. Quality Assurance. The training was provided to data
collectors on how to perform the questionnaire and sam-
pling processing. The filled questionnaires were checked for
their completeness. Media preparations were made based on
the manufacturer’s instruction. Quality control slides were
incorporated during Gram staining. Standard operating pro-
cedures were followed during specimen collection, handling,
transportation, microbiological analysis, and interpretation.
Five percent of media per batch were incubated overnight for
sterility check. Reference strains S. aureusATCC25923,E. coli
ATCC25922, and P. aeruginosaATCC27853were used during
cultivation and antimicrobial susceptibility testing [16].
2.7. Statistical Analysis. Datawas analyzed using SPSS version
22, and descriptive statistics, bivariate, andmultivariate logis-
tic regression were employed. A bivariate logistic regression
model was used to determine the possible association of each
variable with the outcome variable and multivariate analysis
was done to those independent variables with p-value < 0.05
to identify factors that are independently associated with
the dependent variable. P-value <0.05 with 95% confidence
interval was considered as statistically significant.
3. Results
3.1. Sociodemographic Characteristics. This study was con-
ducted among 252 study participants. Out of 224 (88.9%)
were urban dwellers and 28 (11.1%) were rural dwellers. The
mean age of study participants was 40.58 ± 9.9, range 18-67
years old, and 50% being male and the rest female (Table 1).
3.2. Prevalence of Bacterial Pneumonia. Bacterial pneumonia
was observed in 110 (43.7 %) and out of those 59 (46.6 %) of
them were male participants (Table 2). Bacterial pneumonia
was found highest in age group 18-29 (n=15, 50 %) and lowest
in the age group 50-67, 14 (28.6%). Out of the 110 isolates, 95
(42.4%)were isolated fromurban dwellers.The predominant
bacterial species were Klebsiella pneumoniae (n=26, 23.6
%) followed by Streptococcus pneumoniae (n=17, 15.5 %),
Escherichia coli (n=16, 14.5%), Klebsiella spp. (n=15, 13.6%),
Staphylococcus aureus (n=9, 8.2%), Enterobacter spp. (n=7,
6.3%), Pseudomonas aeruginosa (4, n=3.6%), Proteus spp.
(n=4, 3.6%), Citrobacter freundii (n=7, 6.3%), Streptococcus
pyogenes (3, 2.7%), and Haemophilus inﬂuenzae (n=2, 1.8%).
3.3. Antimicrobial Susceptibility Pattern of Bacterial Isolates.
Out of the tested antibiotics, 39.8% (n=40 isolates) were
resistant to co-trimoxazole and 24.5% (n=26) for tetracycline.
In this study, 81.8% (n=9) Gram-positive isolates and 27.6%
(n=8) were resistant to penicillin and erythromycin, respec-
tively (Table 3). Similarly, 10.7% (n=8) of Gram-negative
isolates were resistant to ceftriaxone (Table 3). On the other
hand,most of the isolateswere less resistant to amikacin (n=6,
6.8%) and ciprofloxacin (n=8, 9.1%). Methicillin resistance
was observed in 44.4% (n=4) isolates of S. aureus (Table 3).
Table 1: Sociodemographic characteristics of the study participants
in ART clinics of Mekelle zone, Tigray, Northern Ethiopia, August
2016-December 2016 (n=252).
Variables Frequency Percent (%)
Gender
Male 127 50.4
Female 125 49.6
Age (in years)
18-29 30 11.9
30-39 98 38.9
40-49 75 29.8
50-67 49 19.4
Residence
Urban 224 88.9
Rural 28 11.1
Occupation
Farmer 19 7.5
Employed 78 31
Unemployed 110 43.6
Self-employed 45 17.9
Educational level
Illiterate 42 16.7
Read and write 33 13.1
1-8 80 31.7
9-12 59 23.4
College and above 38 15.1
Multidrug resistance was observed in 18% (n=15) of isolates
(Table 4).
3.4. Associated Risk Factors. All variables with a significance
value in the bivariate analysis were entered in to multiple
logistic regression model and in multivariate analysis the
variables age groups 18-29 (AOR = 3.8, 95 % CI: 1.25-11.52, P
≤ 0.018), age groups 30-39 (AOR = 3.4, 95% CI: 1.37-8.25, P ≤
0.008), recent number of CD4+ cell count less than 350 (AOR
= 2.4, 95 % CI:1.11-5.09, P≤ 0.026), alcohol consumption
(AOR= 7.4, 95 % CI: 2.46-22.11, P ≤ 0.001), andWHO stage of
II HIV infection (AOR= 5.4, 95 % CI: 2.00-14.36, P ≤ 0.001)
were found to have statistically significant association with
bacterial pneumonia. In the bivariate analysis, gender and
occupation failed to show a significant association with the
occurrence of bacterial pneumonia. Although not statistically
significant, bacterial pneumonia was higher in cigarette
smokers, in non-cART users, and in those who interrupt
cART (Table 5).
4. Discussion
In this study, the overall prevalence of bacterial pneumonia
was found to be 43.7%.This is in linewith the studies reported
from Nigeria 42.9 % [19] and India 44.3 % [20]. This is due
to the fact that individuals with compromised immune status
are more susceptible to bacterial infections. On the other
hand, our finding is higher than the findings fromMalawi 29
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Table 2: Rate of bacterial pneumonia with regard to the sociodemographic characteristics among pneumonia suspectedHIV patients in ART
clinics of Mekelle zone, Northern Ethiopia, August 2016-December 2016.
Variables Bacterial occurrence Total
Positive N (%) Negative N (%)
Gender
Male 59 (46.6) 68 (53.5) 127
Female 51 (40.8) 74(59.2) 125
Age (in years)
18-29 15 (50) 15 (50) 30
30-39 47 (48) 51 (52) 98
40-49 34 (45.3) 41 (54.7) 75
50-67 14 (28.6) 35 (71.4) 49
Residence
Urban 95 (42.4) 129 (57.6) 224
Rural 15 (53.6) 13 (46.4) 28
Occupation
Farmer 9 (47.4) 10 (52.6) 19
Employed 32 (41) 46 (59) 78
Unemployed 46 (41.8) 64 (58.2) 110
Self-employed 23 (51.1) 22 (48.9) 45
Educational level
Illiterate 14 (33.3) 28 (66.7) 42
Read and write 10 (30.3) 23 (69.7) 33
1-8 37 (46.3) 43 (53.7) 80
9-12 30 (50.8) 29 (49.2) 59
College and above 19 (50) 19 (50) 38
% [13] and India 18.4 % [21] and lower than the study reported
from Nigeria 55.6% [9]. The inconsistency may be due to
sampling size variation, type of sample used, and immune
status of the study participants.
In our study, K. pneumoniae and S. pneumoniae were the
predominant pathogens isolated as reported in similar studies
from Nepal [22, 23] and India [20]. On the other hand, dif-
ferent predominant isolates, such as E. coli and P. aeruginosa
were reported from Nigeria [9] while S. pneumoniae and H.
inﬂuenzaewere reported fromUganda as dominant bacterial
species [24]. A climatic and geographic variation could be the
possible reasons for the different frequency of the bacterial
isolates in different study area among HIV patients.
E. coliwas the second most common Gram-negative bac-
terium to be isolated in our study; which in agreement with
the study reported fromBahrain [25] andNigeria [9]. Among
the Gram-positives S. aureus was the second most common
species to be isolated; this is consistent with a study reported
from the United States [26], Italy [27], and Greece [28]. The
occurrencemight be due to aspiration of the bacteria from the
previously colonized site, prior hospitalization, contaminated
foods eaten, and mostly systemic spread from blood to the
lungs in these patients [26–28].
WHO recommends co-trimoxazole as an intervention
to reduce infections by opportunistic pathogens including
bacterial pneumonia in HIV positive patients. In this study,
about 39.8% and 24.5% of bacterial isolates were resistant to
co-trimoxazole and tetracycline. This is similar to the study
reported in Nigeria [9] and Tanzania [20].This may be due to
the consistent use of this antibiotic, whichmight contribute to
the development of drug resistance. Out of the tested Gram-
positive isolates, 81.8 % and 27.6 % were resistant to penicillin
and erythromycin respectively. This might be because these
antibiotics have been very commonly prescribed for many
years during the course of infection.
According to the international standard for the defini-
tion of drug resistance [18], 17.9% isolates were multidrug
resistant. We did not have data from our study participants
engaging in self-medication but empirical treatment still is a
contributing factor for the emergence of drug resistance in
these patients [9, 29]. Out of the S. aureus isolates, 44.4 %
were methicillin resistance but because the sample size was
low these results may not be significant. This is higher from
the study reported from Bahrain, 10.5 % [25], and lower from
Italy, 65% [27]
In this study, age groups 18-29 and 30-39, alcohol con-
sumption, recent CD4+ count less than 350 cells/𝜇L, and
WHO stage II of HIV infection showed significant associ-
ation to have bacterial pneumonia. Age groups, 18-29 and
30-39, were 3.8 and 3.4 times more likely to have bacterial
pneumonia, respectively, compared to the age group, 50-67
which is in agreement with studies reported from Nigeria
[9] and Nepal [22]. The reason may be due to the fact that a
large number of younger age groups of our study participants
were within CD4+ cell count less than 350 cells/𝜇L andWHO
stage II compared to those aged between 50 and 67. This
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Table 4: Multidrug resistance patterns of bacterial pneumonia from pneumonia suspected HIV patients in ART clinics of Mekelle zone,
Northern Ethiopia, August-December 2016.
Bacterial Isolates Antibiotics Total
Ro R1 R2 R3 ≥ R4 MDR
K. pneumoniae 9(34.6) 7(30) 8(30.8) 1(3.8) 1(3.8) 2(7.7) 26(100)
E. coli 9(56.3) 3(18.7) 2(12.5) 0(.00) 2(12.5) 2(12.5) 16(100)
Klebsiella spp. 13(86.6) 1(6.7) 0(.00) 0(.00) 1(6.7) 1(6.7) 15(100)
Citrobacter freundii 4(57.1) 1(14.3) 0(.00) 1(14.3) 1(14.3) 2(28.6) 7(100)
Enterobacter spp. 3(42.9) 0(.00) 0(.00) 4(57.1) 0(.00) 4(57.1) 7(100)
Proteus spp. 2(50) 1(25) 1(25) 0(.00) 0(.00) 0(.00) 4(100)
P. aeruginosa 3(75) 1(25) 0(.00) 0(.00) 0(.00) NA 4(100)
H. influenzae 0(.00) 2(100) 0(.00) 0(.00) 0(.00) NA 2(100)
S. pneumoniae 2(11.8) 4(23.5) 10(58.8) 1(5.9) 0(.00) NA 17(100)
S. aureus 3(33.4) 1(11.1) 2(22.2) 1(11.1) 2(22.2) 4(44.4)a 9(100)
S. pyogenes 0(.00) 0(.00) 2(66.7) 1(33.3) 0(.00) NA 3(100)
Total 48(43.6) 21(19.1) 25(22.7) 9(8.2) 7(6.4) 15(17.9)b 110(100)
R0: susceptible to all, R1: resistance to one, R2: resistance to two, R3: resistance to three, and ≥ R4: resistance to four and more antibiotics. MDR= multidrug
resistance. aPercent is computed from the total number of S. aureus;bpercent is computed from a total number of isolates, based on which MDR definition is
applied.
can contribute to increased bacterial pneumonia observed in
our study participants. On the contrary, the studies reported
in Spain [2], Netherlands [30], and France [31] bacterial
pneumonia is also common in older age groups.The immune
status, place of living, diet, deprivation, and affluence are
some of the factors which may play a role in influencing the
level of illness in a given population.
Alcohol consumption is one of the potential risk factors
identified, though our study did not identify the level of
consumption; alcohol consumers were 7.4 times more likely
to have bacterial pneumonia [32]. This may be due to the
fact that alcohol consumers are prone tomore oropharyngeal
secretions due to alteration of their level of consciousness.
Alcohol also has an effect on depressing cough, decreasing
endothelial adherence, lowering chemotaxis, suppressing B
and T-cell expansion, and function which contributes to poor
clearance mechanism of lung cells which is in line with the
studies reported from South Africa [32], Europe [33], and
western North America [34].
In this study, recently low CD4+ cell count was the other
risk factor identified and individuals with recent CD4+ cell
count less than 350 cells/𝜇L were 2.4 timesmore likely to have
bacterial pneumonia compared to those who had CD4+cell
counts ≥ 500 cells/𝜇L, consistent with the study reported
fromUnited States [10] and France [31].WHO stage II of HIV
infection is the other risk factor and these individuals were
5.4 times more likely to have bacterial pneumonia compared
to those WHO stage I individuals. In addition to this, even
though WHO stage III was not significantly associated, the
probability of getting bacterial pneumonia is still higher in
these patients comparing to WHO stage I. This might be
related to unprogrammed activation of the immune system
due to recurrent infections which contribute to damage of
immune cells and the physical barriers of our respiratory
mucosal membrane and simply make susceptible to different
opportunistic infections [6].
In this study, although not statistically significant, bacte-
rial pneumonia was higher among cigarette smokers. Smok-
ing lowers the action and number of cilia and inhibits the
ability to prevent the entry of microorganisms to the respira-
tory tract. This is supported by studies reported earlier which
indicate cigarette smoking increases the risk of bacterial
pneumonia two times compared to nonsmokers [35].
5. Conclusions
In this study, the prevalence of bacterial pneumonia was 43.7
% caused majorly by Gram-negative bacterial species such
as K. pneumoniae and E. coli. In Gram-positive isolates, S.
pneumoniae and S. aureus were the most dominant species
of bacteria. Most isolates were susceptible to amikacin,
ciprofloxacin, and ceftriaxone. Younger age group, the recent
number of CD4+ cell count less than 350 cells, alcohol
consumption, and WHO stage II of HIV infection showed
significant association with bacterial pneumonia. Identifi-
cation of the etiological agent and performing antimicro-
bial susceptibility testing in order to select an appropriate
antimicrobial agent will be important in the management of
bacterial pneumonia and limiting the evolution of resistant
bacteria in the clinical setting.
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Table 5: Bivariate and multivariate logistic regression analysis of factors associated with bacterial pneumonia in pneumonia suspected HIV
patients in ART clinics of Mekelle zone, Northern Ethiopia, August-December 2016.
Variables Bacterial pneumonia COR (95% CI) P-value AOR (95% CI) P-value
Positive Negative
N (%) N (%)
Gender
Male 59 (46.6) 68 (53.5) 1.3 (0.76-2.07) 0.366
Female 51 (40.8) 74 (59.2) 1
Age (in years)
18-29 15 (50) 15 (50) 2.5 (0.97-6.44) ∗ 0.058 3.8 (1.25-11.52) ∗ 0.018
30-39 47 (48) 51 (52) 2.3 (1.10-4.81) ∗ 0.026 3.4 (1.37-8.25) ∗ 0.008
40-49 34 (45.3) 41 (54.7) 2.1 (0.96-4.47) 0.063 2.0 (0.81-5.06) 0.132
50-67 14 (28.6) 35 (71.4) 1 1
Occupation
Employed 32 (41) 46 (59) 1
Farmer 9 (47.4) 10 (52.6) 1.1 (0.35-3.72) 0.825
Unemployed 46 (40) 64 (60) 0.9 (0.30-2.66) 0.849
Self-employed 23 (51.1) 22 (48.9) 0.6 (0.31-1.35) 0.248
Recent CD4+ cells/𝜇l
<350 56 (57.7) 41 (42.3) 3.3 (1.7-6.34) ∗ 0.001 2.4 (1.11-5.09)∗ 0.026
350-500 34 (39.1) 53 (60.9) 1.5 (0.78-3.03) 0.211 1.2 (0.54-2.58) 0.686
>500 20 (29.4) 48 (70.6) 1 1
Cigarette smoking
Yes 13 (65) 7 (35) 2.6 (0.99-6.72) 0.051 1.6 (0.44-5.50) 0.488
No 97 (41.8) 135 (58.2) 1 1
Use cART
Yes 100 (41.8) 139 (58.2) 1 1
No 10 (76.9) 3 (23.1) 4.6 (1.24-17.27) 0.022 0.00 1.000
Ever interrupt cART
Yes 16 (69.6) 7 (30.4) 3.6 (1.43-9.17) ∗ 0.007 2.5 (0.87-7.23) 0.090
No 84 (38.7) 133 (61.3) 1 1
Alcohol consumption
Yes 22 (81.5) 5 (18.5) 6.9 (2.5-18.76) ∗ 0.001 7.4 (2.46-22.11)∗ 0.001
No 88 (39.1) 137 (60.9) 1 1
WHO Stage
I 80 (38.6) 127 (61.4) 1 1
II 22 (75.9) 7 (24.1) 5.0 (2.04-12.22)∗ 0.001 5.4 (2.00-14.36)∗ 0.001
III 8 (50) 8 (50) 1.6 (0.57-4.40) 0.374 0.5 (0.13-1.97) 0.329
COR=crude odds ratio; CI=confidence interval; AOR=adjusted odds ratio; 1: referent; ∗statically significant.
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